Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 107Genitourinary 5Gynecologic 2Gastrointestinal 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Other 1Myeloid 1Lymphoid 1Endocrine 1Classical hematology 1CNS 1

Conditions

Somatostatinoma 1Mucositis 1Insulinoma 1Glucagonoma 1Gastrinoma 1Carcinoma, Renal Cell 1Carcinoma, Islet Cell 1Breast Neoplasms 1

Interventions

Exercise 9exemestane 4Psychiatric Rehabilitation 4Tamoxifen 3Methods 3Metformin 3Letrozole 3Early Intervention, Educational 3Diet Therapy 3Bupropion 3Bariatric Surgery 3Anastrozole 3Vitamin D 2Therapeutics 2Sugars 2Specimen Handling 2Naltrexone 2Mammography 2Diet, Mediterranean 2Counseling 2Cognitive Behavioral Therapy 2Cholecalciferol 2Blood Specimen Collection 2rosiglitazone-metformin combination 1bupropion hydrochloride, naltrexone hydrochoride drug combination 1Yoga 1Walking 1Tirzepatide 1Testosterone Propionate 1Testosterone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × Everolimus × Other × Clear all
NCT02273752 2017-02-03

Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer

Emory University

Phase 2 Terminated
2 enrolled 5 charts
BreastEndocrineGenitourinaryOther

Breast Neoplasms, Carcinoma, Renal Cell, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡